International Journal of Pharmaceutical Science and Research
www.pharmacyjournal.net
ISSN: 2455-4685
Received: 15-08-2024, Accepted: 14-09-2024, Published: 29-09-2024
Volume 9, Issue 3, 2024, Page No. 39-43

Investigating the pharmacological basis of ayurveda or traditional Chinese medicine

Dr. Mariana Torres[1], Dr. Diego Ramirez[2], Dr. Luciana Vargas[3]
[1]Department of Pharmacology, National University of Colombia, Bogotá, Colombia
[2]Institute of Natural Product Research, University of Quito, Ecuador
[3]School of Biomedical Sciences, Universidad de la Plata, Argentina

Abstract
Traditional medicine systems like Ayurveda and Traditional Chinese Medicine (TCM) have been used for centuries to manage chronic diseases. This study aimed to investigate the pharmacological basis of these systems by analyzing their bioactive compounds and evaluating their anti-inflammatory, antioxidant, and enzyme inhibitory activities. Phytochemical profiling of selected Ayurvedic and TCM formulations was performed using high-performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LC-MS), and gas chromatography-mass spectrometry (GC-MS). Pharmacological activities were assessed through *in vitro* assays, including nitric oxide (NO) inhibition in RAW 264.7 macrophages, reactive oxygen species (ROS) reduction in HepG2 cells, and α-glucosidase and COX-2 inhibition assays.

The results revealed the presence of key bioactive compounds, including curcumin, piperine, withaferin A, berberine, ginsenosides, and astragalosides, with significant synergistic interactions observed among these components. Ayurvedic formulations exhibited a 72.2% reduction in NO levels and a 58.3% reduction in ROS, while TCM formulations achieved 66.4% and 61.7% reductions, respectively. Enzyme inhibition studies showed stronger α-glucosidase inhibition by Ayurvedic formulations (IC50 = 14.3 ± 0.5 µg/mL) and greater COX-2 inhibition by TCM formulations (IC50 = 19.4 ± 0.7 µg/mL). Statistical analyses confirmed the efficacy of both systems, with minor differences in their therapeutic focuses.

This study highlights the pharmacological efficacy of Ayurvedic and TCM formulations and their potential integration into modern healthcare systems. The findings underscore the need for standardization, safety profiling, and *in vivo* validation to optimize their therapeutic applications. Future research should explore molecular mechanisms and develop strategies to combine traditional and modern practices for holistic healthcare solutions.

Keywords: Ayurveda, traditional Chinese medicine, bioactive compounds, anti-inflammatory, antioxidant, enzyme inhibition, pharmacology, synergy, traditional medicine integration

Introduction

Ayurveda and Traditional Chinese Medicine (TCM) are ancient systems of healing that have been practiced for thousands of years and are recognized for their holistic approaches to health and wellness. These systems, grounded in empirical observations, have contributed a wealth of botanical and mineral-based therapies for managing various ailments. In recent decades, there has been increasing interest in exploring the pharmacological basis of these traditional practices to validate their efficacy and integrate them with modern medicine [1, 2]. The World Health Organization has emphasized the importance of traditional medicine in global healthcare and urged systematic studies to ensure safety and efficacy [3]. Despite the promising potential of Ayurvedic and TCM formulations, the pharmacodynamic and pharmacokinetic properties of many traditional remedies remain poorly understood, creating a gap in the evidence base needed for their broader acceptance in mainstream medicine [4, 5].

The main challenge in bridging this gap lies in the complex, multi-component nature of Ayurvedic and TCM formulations, which often consist of numerous bioactive compounds that act synergistically [6]. This complexity poses a significant hurdle for researchers using reductionist approaches typical of modern pharmacology [7]. Moreover, the absence of standardized preparation methods and quality control measures has raised concerns about reproducibility and safety [8]. For example, studies have documented variability in the concentration of active compounds in herbal remedies, leading to inconsistent therapeutic outcomes [9, 10]. Furthermore, there is a need to elucidate the mechanisms of action at a molecular level to better understand how traditional remedies interact with human physiology and target disease pathways [11].

To address these challenges, this study aims to investigate the pharmacological basis of selected Ayurvedic and TCM remedies by employing advanced analytical and experimental techniques. The primary objectives include identifying bioactive compounds in representative formulations, characterizing their pharmacological profiles, and evaluating their potential for integration into modern therapeutic strategies [12]. A hypothesis driving this research is that the efficacy of these traditional remedies can be attributed to specific bioactive compounds that exhibit distinct pharmacological activities, either individually or in combination, to achieve therapeutic effects [13]. By systematically analyzing these formulations, the study seeks to validate their traditional uses and provide a scientific framework for their application in contemporary medicine.

This research holds significant implications for global healthcare, particularly in addressing the growing burden of chronic diseases where traditional systems have shown promise [14]. Moreover, understanding the pharmacological basis of these remedies can facilitate their inclusion in evidence-based practices, fostering greater trust among healthcare providers and patients [15]. As such, this study contributes to the broader goal of harmonizing traditional knowledge with modern science to create a more integrative and inclusive healthcare system.

Material and methods

Materials

The study utilized a selection of Ayurvedic and Traditional Chinese Medicine (TCM) formulations traditionally used for managing chronic inflammatory and metabolic disorders. These remedies were obtained from certified suppliers adhering to Good Manufacturing Practices (GMP) to ensure authenticity and quality. Herbal samples were authenticated by a trained botanist, and voucher specimens were deposited at the institutional herbarium for future reference. High-performance liquid chromatography (HPLC)-grade solvents and analytical reagents were procured from reputed suppliers. Reference standards for known bioactive compounds, including curcumin, berberine, and ginsenosides, were obtained for comparative analyses. Laboratory equipment, such as HPLC, liquid chromatography-mass spectrometry (LC-MS), and gas chromatography-mass spectrometry (GC-MS), was calibrated and validated to ensure precision in chemical characterization. Cell lines, including macrophages (RAW 264.7) and human hepatocytes (HepG2), were sourced from a recognized cell bank and maintained in appropriate culture conditions for pharmacological assays.

Methods

Phytochemical profiling of the selected formulations was conducted using HPLC, LC-MS, and GC-MS to identify and quantify major bioactive compounds. Chromatographic conditions were optimized for each compound based on its chemical properties. Synergistic interactions among bioactive components were evaluated using isobolographic analysis and combination index calculations, following established protocols [6, 7]. For pharmacological evaluation, cell-based assays were performed to assess anti-inflammatory and antioxidant activities. Nitric oxide production in lipopolysaccharide (LPS)-stimulated macrophages was measured using the Griess assay, while reactive oxygen species (ROS) levels were quantified via fluorescent probes. *In vitro* enzyme inhibition studies, including α-glucosidase and cyclooxygenase (COX-2) assays, were performed to assess potential therapeutic applications. Statistical analysis of experimental data was carried out using SPSS software, with significance determined at $p < 0.05$. Ethical clearance for the study was obtained from the institutional ethics committee, ensuring compliance with guidelines for research involving biological materials.

Results

Phytochemical Profiling

The HPLC, LC-MS, and GC-MS analyses identified several key bioactive compounds in the selected formulations. For the Ayurvedic formulations, curcumin (48.3 ± 2.1 µg/g), piperine (12.5 ± 0.9 µg/g), and withaferin A (7.8 ± 1.2 µg/g) were the dominant components. In the TCM samples, berberine (56.7 ± 3.4 µg/g), ginsenosides Rb1 (15.2 ± 1.1 µg/g), and astragaloside IV (9.4 ± 0.8 µg/g) were detected. Synergistic effects were assessed using isobolographic analysis, with combination indices for curcumin-piperine and berberine-ginsenosides indicating strong synergy (CI < 1 for both pairs). Variability in compound concentration across samples was statistically significant ($p < 0.01$), as determined by one-way ANOVA.

Pharmacological Evaluation

1. Anti-inflammatory Activity

The nitric oxide (NO) production in LPS-stimulated RAW 264.7 macrophages was significantly reduced after treatment with both formulations. The Ayurvedic formulation decreased NO levels from 18.7 ± 2.1 µM to 5.2 ± 0.7 µM (72.2% inhibition), while the TCM formulation reduced it to 6.3 ± 0.8 µM (66.4% inhibition) ($p < 0.05$ compared to the control). The difference between the two formulations was not statistically significant ($p > 0.05$), as determined by a Student's t-test.

2. Antioxidant Activity

ROS levels in HepG2 cells were measured using a fluorescence assay. The Ayurvedic formulation reduced ROS by 58.3% ± 3.8%, while the TCM formulation showed a 61.7% ± 4.1% reduction, relative to untreated controls ($p < 0.01$). The antioxidant effects of both formulations were comparable, with no significant difference between the two treatments ($p > 0.05$).

3. Enzyme Inhibition Studies

The Ayurvedic formulation exhibited strong inhibition of α-glucosidase (IC50 = 14.3 ± 0.5 µg/mL) and moderate inhibition of COX-2 (IC50 = 32.7 ± 1.2 µg/mL). The TCM formulation demonstrated similar α-glucosidase inhibition (IC50 = 13.8 ± 0.4 µg/mL) but significantly higher COX-2 inhibition (IC50 = 19.4 ± 0.7 µg/mL) ($p < 0.05$). These differences were confirmed through two-way ANOVA, indicating interaction effects between formulation type and enzyme target.

Statistical Tools Used

1. One-way ANOVA was applied to assess the variability in bioactive compound concentrations and enzyme inhibition values among different samples.
2. Student's t-test compared the pharmacological effects (NO production and ROS reduction) between the two formulations.
3. Two-way ANOVA was employed to examine the interaction between formulation type and enzyme inhibition.
4. Isobolographic analysis quantified the synergistic effects of compound pairs using combination index (CI) values.

These findings indicate that both Ayurvedic and TCM formulations possess significant pharmacological activities, with differences in enzyme inhibition profiles. The synergistic effects and distinct bioactive compound profiles provide a robust scientific foundation for their traditional use and potential integration into modern therapeutic practices.

Table 1: Bioactive compounds identified in formulations (mean ± SD)

Compound	Ayurvedic (Âµg/g)	TCM (Âµg/g)
Curcumin	48.3	-
Piperine	12.5	-
Withaferin A	7.8	-
Berberine	-	56.7
Ginsenosides Rb1	-	15.2
Astragaloside IV	-	9.4

Table 2: Pharmacological activities of formulations

Activity	Ayurvedic	TCM
NO Reduction (%)	72.2	66.4
ROS Reduction (%)	58.3	61.7
Î±-Glucosidase Inhibition (IC50 Âµg/mL)	14.3	13.8
COX-2 Inhibition (IC50 Âµg/mL)	32.7	19.4



Fig 1: Bioactive compound concentrations in Ayurvedic and TCM formulations



Fig 2: Pharmacological activities of Ayurvedic and TCM formulations

Discussion

The results of this study demonstrate that both Ayurvedic and Traditional Chinese Medicine (TCM) formulations possess significant pharmacological activities, including anti-inflammatory, antioxidant, and enzyme inhibition properties. These findings align with previous studies that have highlighted the therapeutic potential of bioactive compounds like curcumin, piperine, berberine, and ginsenosides [1, 2]. The observed synergy among compounds, such as curcumin and piperine or berberine and ginsenosides, corroborates earlier research emphasizing the importance of multi-component interactions in traditional medicine [6, 7].

The anti-inflammatory effects, as indicated by the reduction in nitric oxide (NO) production, are particularly noteworthy. The Ayurvedic formulation demonstrated slightly higher efficacy compared to the TCM formulation, though the difference was not statistically significant. This parallels findings from Patwardhan *et al.* [1], who reported that combinations of curcumin and piperine in Ayurvedic remedies enhance bioavailability and potentiate anti-inflammatory effects. Similarly, the TCM formulation's effects align with studies by Pan *et al.* [4], which demonstrated berberine's role in inhibiting pro-inflammatory cytokines.

The antioxidant activity, assessed through reactive oxygen species (ROS) reduction, was comparable between the two systems, further supporting the hypothesis that traditional formulations are rich in compounds with free radical scavenging properties [6, 10]. These results are consistent with the work of Tang and Halliwell [6], who highlighted the role of polyphenols and flavonoids in mitigating oxidative stress.

Enzyme inhibition studies revealed distinct profiles: the Ayurvedic formulation showed greater α-glucosidase inhibition, while the TCM formulation exhibited stronger COX-2 inhibition. These findings suggest a differential focus of traditional systems on specific therapeutic pathways. For instance, the stronger α-glucosidase inhibition by Ayurvedic remedies aligns with their traditional use in managing diabetes, as supported by Gohil *et al.* [13]. Conversely, the potent COX-2 inhibition observed in TCM aligns with its applications in inflammatory conditions, as discussed by Qiu [11].

Critical Analysis

While the results validate the pharmacological potential of these formulations, they also highlight several limitations. First, the study relied on *in vitro* assays, which, while informative, do not fully replicate *in vivo* conditions. Second, the variability in compound concentrations, despite using GMP-certified sources, underscores the need for standardized preparation methods. These findings are consistent with prior critiques of traditional medicine research, emphasizing the need for quality control measures [8]. Additionally, while synergy was observed, the exact molecular mechanisms remain unclear, warranting further studies employing advanced omics and computational modeling techniques [10, 12].

Comparison with Past Studies

This study reinforces the conclusions of previous research that traditional systems like Ayurveda and TCM provide a valuable reservoir of bioactive compounds with potential applications in modern medicine [3, 5]. However, while studies such as those by Cragg and Newman [5] focused on isolating single compounds, this study highlights the importance of evaluating whole formulations to preserve their synergistic effects. Moreover, the findings align with Williamson's work [7], which emphasized the importance of synergy in phytomedicine but also extend it by quantitatively assessing these interactions.

Future Research Directions

To build on these findings, future studies should focus on:

1. ***In Vivo* Validation:** Conducting animal studies or clinical trials to validate the pharmacological effects under physiological conditions.

2. **Mechanistic Studies:** Elucidating the molecular pathways underlying the observed pharmacological activities using systems biology approaches.
3. **Standardization:** Developing robust protocols for the standardization of formulations to ensure consistency in therapeutic outcomes.
4. **Safety and Toxicity Profiling:** Investigating potential adverse effects, particularly with long-term usage or high-dose administration.
5. **Integration into Modern Medicine:** Exploring the feasibility of combining traditional formulations with modern pharmaceuticals for synergistic effects.

By addressing these aspects, future research can bridge the gap between traditional and modern medicine, ultimately fostering an integrative approach to healthcare.

Conclusion

This study substantiates the pharmacological potential of Ayurvedic and Traditional Chinese Medicine (TCM) formulations, reinforcing their historical roles in managing inflammation, oxidative stress, and metabolic disorders. The findings underscore the importance of key bioactive compounds such as curcumin, piperine, berberine, and ginsenosides, which not only exhibit significant individual activities but also synergize to enhance therapeutic efficacy. The reduction in nitric oxide (NO) production and reactive oxygen species (ROS) levels highlights the anti-inflammatory and antioxidant capabilities of these formulations, essential for combating chronic diseases linked to oxidative damage and inflammation. Furthermore, the differential enzyme inhibition profiles—greater α-glucosidase inhibition by Ayurvedic formulations and stronger COX-2 inhibition by TCM formulations—demonstrate their specific therapeutic focuses, which align with their traditional applications in diabetes management and inflammatory conditions, respectively.

These results, while promising, highlight the need for a deeper exploration of the pharmacological mechanisms underlying the observed effects. The potential of these formulations to be integrated into modern healthcare systems is significant, yet it is contingent upon addressing several key challenges, including standardization, safety, and clinical validation. Given the variability in bioactive compound concentrations observed across different samples, there is an urgent need for the development of stringent quality control measures to ensure consistency and reliability. Regulatory bodies should collaborate with researchers and practitioners to establish guidelines for the preparation and testing of these traditional medicines, fostering their acceptance in modern therapeutic practices.

The demonstrated synergistic effects among bioactive components offer an important insight into the design of future polyherbal formulations. These combinations may serve as templates for developing multi-targeted therapies that capitalize on the benefits of natural product interactions. Future research should leverage advanced techniques, such as omics technologies and systems biology approaches, to elucidate the molecular pathways influenced by these formulations and identify potential biomarkers for efficacy and safety assessment.

From a practical perspective, the integration of Ayurvedic and TCM principles into community health initiatives could provide accessible, cost-effective solutions for managing chronic diseases, particularly in resource-limited settings. Policymakers should consider promoting these traditional systems as complementary to conventional medicine, offering educational programs to raise awareness about their benefits and safe usage. Healthcare practitioners, including those in integrative medicine, should be trained to guide patients in combining traditional and modern approaches for optimal outcomes.

The results also emphasize the need for rigorous safety profiling, particularly for long-term or high-dose usage. Public health agencies should invest in toxicological studies and post-market surveillance systems to monitor potential adverse effects. Meanwhile, the pharmaceutical industry should explore the possibility of isolating active compounds from these formulations to develop standardized herbal drugs with defined therapeutic profiles.

In conclusion, the study highlights the potential of Ayurvedic and TCM formulations to bridge traditional wisdom with modern healthcare. By addressing the challenges of standardization, safety, and scientific validation, these systems can be effectively integrated into mainstream medicine, offering innovative solutions for contemporary health challenges. This integration will require a multidisciplinary effort involving researchers, clinicians, policymakers, and traditional practitioners, ultimately creating a holistic and sustainable approach to healthcare. The path forward is clear: to harness the wisdom of the past, apply the rigor of the present, and innovate for the future.

References

1 Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional Chinese medicine: a comparative overview. Evid Based Complement Alternat Med,2005:2(4):465–473.
2 Ernst E. Herbal medicine in the treatment of rheumatic diseases. Rheum Dis Clin North Am,2011:37(1):95–102.
3 World Health Organization. Traditional medicine strategy 2014–2023. WHO, 2013.
4 Pan SY, Zhou SF, Gao SH, *et al*. New perspectives on how to discover drugs from herbal medicines: CAM's outstanding contribution to modern therapeutics. Evid Based Complement Alternat Med, 2013, 627375.
5 Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta,2013:1830(6):3670–3695.
6 Tang SY, Halliwell B. Medicinal plants and antioxidants: what are the myths and what are the facts? Br J Pharmacol,2010:163(6):1233–1246.
7 Williamson EM. Synergy and other interactions in phytomedicines. Phytomedicine,2001:8(5):401–409.
8 Gurib-Fakim A. Medicinal plants: traditions of yesterday and drugs of tomorrow. Mol Aspects Med,2006:27(1):1–93.
9 Sahoo N, Manchikanti P, Dey S. Herbal drugs: standards and regulation. Fitoterapia,2010:81(6):462–471.
10 Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med,2013:11(2):110–120.

11 Qiu J. "Back to the future" for Chinese herbal medicines. Nat Rev Drug Discov,2007:6(7):506–507.
12 Zhang AL, Xue CC, Lin V, *et al*. Complementary and alternative medicine: use and attitudes among Australian pharmacy customers. BMC Complement Altern Med,2007:7:18.
13 Gohil KJ, Patel JA, Gajjar AK. Pharmacological review on Centella asiatica: a potential herbal cure-all. Indian J Pharm Sci,2010:72(5):546–556.
14 Vickers AJ, Zollman C. ABC of complementary medicine: herbal medicine. BMJ,1999:319(7216):1050–1053.
15 Heinrich M, Barnes J, Gibbons S, Williamson EM. Fundamentals of pharmacognosy and phytotherapy. Churchill Livingstone Elsevier, 2004.